ConductScience.org, home

Comparison · NCT03096314-900f421f

High Dose Vitamin D Formulation vs Placebo: All-cause, All-location Mortality to Day 90

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. High Dose Vitamin D Formulation vs Placebo: All-cause, All-location Mortality to Day 90. Trial comparisons, record NCT03096314-900f421f. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03096314-900f421f

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.2350.2010.273wilson
Risk in group 20.2060.1740.243wilson
Risk difference, group 1 minus group 20.029-0.02110.0788newcombe hybrid score
Risk ratio, group 1 over group 21.140.9091.43log
Odds ratio, group 1 over group 21.180.8851.58log
Number needed to treat, for one more participant with the outcome on High Dose Vitamin D Formulation than on Placebo34.5from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1High Dose Vitamin D FormulationA single dose of 540,000 IU vitamin D3 will be administered within 2 hours of randomization time.~Vitamin D3: 540,000 IU vitamin D3125531OG000
Group 2Placebo
A single, liquid enteral placebo dose administered either orally or via naso/orogastric tube will be administered within 2 hours of randomization time.~Placebo: A single, liquid enteral dose administered either orally or via naso/orogastric tube
109528OG001

Outcome

Type
PRIMARY
Title
All-cause, All-location Mortality to Day 90
Description
Vital status of the patient at day 90 was determined using any of the following methods: medical record review, phone calls to patient, proxy or healthcare facility, review of obituaries, or information from the Centers for Disease Control and Prevention's National Death Index (NDI).
Time frame
90 days after randomization
Population
The primary analysis included subjects who had confirmed vitamin D deficiency by LC/MS/MS testing.

Source ClinicalTrials.gov

Trial

Title
Vitamin D to Improve Outcomes by Leveraging Early Treatment
NCT number
NCT03096314
Phases
PHASE3
Conditions
Acute Respiratory Distress Syndrome, Vitamin D Deficiency, Critical Illness
Interventions
Vitamin D3, Placebo
Lead sponsor
Massachusetts General Hospital
Results first posted
2020-01-27

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03096314-900f421f